# PT-141 Research: The Bremelanotide Studies, Read in Order > PT-141 research from preclinical models to the Phase 3 RECONNECT trials and the FDA label — mechanism, efficacy, safety, and the open questions. Fully cited. The mechanism studies, the pivotal trials, the long-term extension, and the negative findings — each result attributed to its study. ## The gist PT-141 research runs from animal pharmacology in the early 2000s to two large human trials and an FDA approval in 2019. The early studies established the mechanism: PT-141, a synthetic alpha-MSH analogue, switches on melanocortin receptors (MC3R/MC4R) in the brain, produced erections in rats and primates, activated hypothalamic neurons, and produced dose-dependent erectile activity in men [1]. Female-rat work then showed it selectively increases desire-driven behavior [2]. The human story peaks with RECONNECT, two identical Phase 3 trials in premenopausal women with HSDD that supported approval [3], plus a 52-week safety extension [4] and a brain-imaging study explaining the central mechanism [5]. A 2025 hamster study adds a careful negative finding about the reward circuit [6]. The FDA label anchors the dose, pharmacokinetics, and warnings [7]. This page walks that record study by study; the full citations live on the [PT-141 references](/references) page. ## Mechanism and preclinical foundation The foundational pharmacology was set out by Molinoff and colleagues: PT-141 is an agonist at melanocortin receptors (MC3R/MC4R) expressed primarily in the central nervous system, and systemic administration produced penile erections in rats and nonhuman primates while increasing c-Fos (a marker of neuronal activation) in the hypothalamus — and produced rapid, dose-dependent erectile activity in men with erectile dysfunction [1]. Pfaus and colleagues then showed in female rats that PT-141 selectively stimulated appetitive, solicitational sexual behaviors without affecting lordosis, pacing, or general motor activity — evidence that central melanocortin systems help regulate female sexual desire, and the first pharmacological agent reported to act on appetitive female sexual behavior [2]. A broader review situated bremelanotide within melanocortin pharmacology for male and female sexual dysfunction [11]. ## The Phase 3 RECONNECT trials The pivotal evidence is two identical Phase 3 randomized controlled trials — RECONNECT — enrolling 1,267 premenopausal women with HSDD. Bremelanotide 1.75 mg given subcutaneously as needed met both coprimary endpoints: a statistically significant improvement in sexual desire (integrated FSFI-desire +0.35, P<.001) and a reduction in desire-related distress (integrated FSDS-DAO item 13 -0.33, P<.001) versus placebo over 24 weeks [3]. The most common adverse events were nausea, flushing, and headache [3]. A 52-week open-label extension enrolled 684 women and found no new safety signals, with sustained desire improvements; the most common drug-related treatment-emergent events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4]. An accessible approval-era review summarized the same pharmacology, efficacy, dosing, and adverse-event data [12]. ## Brain imaging and a careful negative finding A randomized, double-blind, placebo-controlled crossover fMRI study of 31 premenopausal women with HSDD provided mechanistic human evidence: MC4R agonism significantly increased sexual desire for up to 24 hours and altered task-based brain processing — enhanced amygdala-insula functional connectivity and cerebellar/supplementary-motor activity — in response to erotic stimuli [5]. Balancing the picture, a 2025 study in female Syrian hamsters found MC3R/MC4R mRNA concentrated in ventral tegmental area dopamine neurons, but reported that neither low- nor high-dose bremelanotide changed melanocortin-receptor mRNA expression in the mesolimbic dopamine system, and that bremelanotide did not enhance sexual reward in a conditioned-place-preference test — suggesting it does not act on the VTA-nucleus accumbens reward circuit [6]. Good research includes its negative results. ## Regulatory context and the open questions Bremelanotide received its first regulatory approval in the United States in June 2019 for HSDD in premenopausal women, as a 1.75 mg subcutaneous as-needed injection [10]. Its approval landed in a strong year for peptide drugs — a 2019 review of FDA-approved peptide and oligonucleotide therapeutics situates it within that broader trend [9]. The US prescribing information is the authoritative source for dose, pharmacokinetics, and warnings [7]. The open questions are explicit: independent re-analyses argue the trial effects are small; nausea drives discontinuation; transient blood-pressure increases shape the contraindications; and uses in men, postmenopausal women, and for performance remain off-label or unapproved. The compound is well-characterized for one indication and lightly characterized for the rest. --- A blue-phosphor terminal reading of the PT-141 (bremelanotide) record — the one approved use logged first, the label dose and trial figures read back verbatim, the off-label and research-chemical lines flagged amber, and the unverified field reports fenced off as such; no clinic behind the prompt and nothing here dosed, sourced, prescribed, or sold.